

1 Supporting Information for

2 **Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-**  
3 **guided DNA-binding modules**

4

5 Arik Shams<sup>1,\*</sup>, Sean A. Higgins<sup>1,2,3,\*</sup>, Christof Fellmann<sup>1,4,5</sup>, Thomas J. Laughlin<sup>1,6</sup>, Benjamin L. Oakes<sup>1,2,3</sup>, Rachel  
6 Lew<sup>4</sup>, Maria Lukarska<sup>1,2</sup>, Madeline Arnold<sup>1</sup>, Brett T. Staahl<sup>1,2,3</sup>, Jennifer A. Doudna<sup>1,2,4,7,8,9,10,11</sup>, David F. Savage<sup>1,^</sup>

7

8 Affiliations:

9 <sup>1</sup>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA

10 <sup>2</sup>Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA

11 <sup>3</sup>Scribe Therapeutics, Alameda, CA 94501, USA

12 <sup>4</sup>Gladstone Institutes, San Francisco, CA 94158, USA

13 <sup>5</sup>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158,  
14 USA

15 <sup>6</sup>Division of Biological Sciences, University of San Diego, San Diego, CA 92093, USA

16 <sup>7</sup>Graduate Group in Biophysics, University of California, Berkeley, Berkeley, CA 94720, USA

17 <sup>8</sup>Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA

18 <sup>9</sup>Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, CA 94720, USA

19 <sup>10</sup>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720,  
20 USA

21 <sup>11</sup>Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA

22

23 \* These authors contributed equally to this work.

24 ^Correspondence: savage@berkeley.edu.

## 25 **Experimental Design**

26

### 27 **Molecular Biology**

28

29 All restriction enzymes were ordered from New England Biolabs (NEB). Polymerase Chain Reaction  
30 (PCR) was performed using Q5 High-Fidelity DNA Polymerase from NEB. Ligation was performed using T4 DNA  
31 Ligase from NEB. Agarose gel extraction was performed using the Zymoclean Gel DNA Recovery kit, and PCR  
32 clean-up was performed using the 'DNA Clean & Concentrator', both from Zymo Research. Plasmids were  
33 isolated using the QIAprep Spin Miniprep Kit (Qiagen). All DNA-modifying procedures were performed  
34 according to the manufacturers' instructions.

35

36

### 37 **MISER library construction: Plasmid Recombineering**

38

39 Two sets of 1368 oligonucleotides were designed and ordered as Oligonucleotide Library Synthesis  
40 (OLS) from Agilent Technologies (Table S1). Oligonucleotides were designed to insert a six base pair (bp)  
41 recognition sequence for either the restriction enzyme NheI or SpeI between every codon in dCas9 (Figure  
42 S1A). The full list of ordered oligonucleotides is available as Auxiliary Supplementary Materials -  
43 Recombineering Oligonucleotides. Internal priming sites were included in order to amplify NheI or SpeI specific  
44 oligonucleotide libraries. A modified amplification procedure was performed. In a 50  $\mu$ L PCR reaction, 10 ng of  
45 template oligonucleotide library was amplified according to manufacturer's instructions, but with an extension  
46 time of only five seconds, and a total of only 15 cycles. 1.5% dimethyl sulfoxide (DMSO) was also included in  
47 the PCR reaction. These modifications were empirically determined in order to minimize undesirable higher  
48 order PCR products that were observed to be produced by amplification. These side products are likely the  
49 result of complementary oligonucleotides priming one another. Notably this phenomenon is likely inherent to  
50 amplification of a library of DNA tiled across a common sequence--in this case dCas9. PCR primers can be  
51 found in Table S6 and Auxiliary Supplementary Materials - Primer Sequences. 24 such reactions were typically  
52 performed in parallel and then combined, followed by concentration with Zymo DNA Clean & Concentrator.  
53 Bsmbl restriction digestion was then used to remove priming ends, followed by a second concentration with  
54 Zymo DNA Clean & Concentrator, resulting in mature double-stranded recombineering-competent DNA.

55 Plasmid recombineering was performed as described in Higgins et al. 2017, using strain EcNR2  
56 (Addgene ID: 26931) to generate MISER libraries in plasmid pSAH060. Plasmid sequences can be found in  
57 Auxiliary Supplementary Materials - Plasmid Sequences. Briefly, mature double-stranded recombineering-  
58 competent DNA at a final volume of 50  $\mu$ L of 1  $\mu$ M, plus 10 ng of pSAH060, was electroporated into 1 mL of  
59 induced and washed EcNR2 using a 1 mm electroporation cuvette (BioRad GenePulser). A Harvard Apparatus  
60 ECM 630 Electroporation System was used with settings 1800 kV, 200  $\Omega$ , 25  $\mu$ F. Three replicate  
61 electroporations were performed, then individually allowed to recover at 30° C for 1 hr in 1 mL of SOC (Teknova)  
62 without antibiotic. LB (Teknova) and kanamycin (Fisher) at 60  $\mu$ g/mL was then added to 6 mL final volume and  
63 grown overnight. A sample of recovered culture was diluted and plated on kanamycin to estimate the total  
64 number of transformants, typically  $>10^7$ . Cultures were miniprepmed and combined the next day. Plasmid  
65 recombineering is relatively inefficient, and only a fraction of recovered plasmids contained successful NheI or  
66 SpeI insertions. In order to recover completely penetrant libraries, an intermediate cloning step was performed.  
67 A PCR product conferring resistance to chloramphenicol was cloned into both libraries of pSAH060 plasmids  
68 (Auxiliary Supplementary Materials - Chloramphenicol Selection). This PCR product contained either flanking

69 NheI restriction sites or SpeI restriction sites, such that only modified pSAH060 plasmids (possessing NheI or  
70 SpeI restriction sites) could obtain chloramphenicol resistance through NheI/SpeI digestion and subsequent  
71 ligation. Libraries were then purified (Zymo) and transformed into XLI-Blue competent cells for overnight  
72 selection in chloramphenicol (Amresco) at 25 µg/mL, followed by plasmid isolation the next day. Samples of  
73 recovered cultures were also plated on both kanamycin alone (native pSAH060 resistance) and chloramphenicol  
74 alone (resistance mediated by successful recombineering insertion) to estimate the fraction of modified  
75 plasmids and therefore the restriction library size. Recombineering efficiencies were observed at ~0.5% by this  
76 method, indicating restriction library sizes of ~50,000, well above the number of unique insertion sites per library  
77 (1,368). Finally, chloramphenicol resistant pSAH060 libraries were digested with either NheI or SpeI as  
78 appropriate, removing the chloramphenicol cassette. The libraries were run on an agarose gel, and the 5953  
79 bp (5947 bp pSAH060 + 6 bp inserted restriction site) linear band corresponding to each library was gel  
80 extracted. To construct deletion variants composed of N- and C- terminal dCas9 fragments, one µg of each  
81 library was mixed and digested with BsaI, then cleaned up (Zymo). The resulting DNA mixture contained  
82 equimolar free dCas9 N- and C-terminal fragments, as well as equimolar pSAH060 vector backbone. This  
83 mixture was then ligated in the presence of SpeI and NheI, 'locking' dCas9 fragments together by one of two  
84 six bp scar sites not recognized by either enzyme (Figure S1B). The ligated MISER library was transformed into  
85 XL1-Blue, grown overnight and plasmids were isolated the next day. The MISER library of dCas9 is quite large,  
86 with 936,396 possible deletions  $(N(N + 1) / 2, N = 1368)$ , and all cloning steps were performed with validation  
87 that  $>10^7$  transformants were obtained.

88

89

#### 90 **MISER library construction: library size selection**

91

92 The MISER library is theoretically composed of all possible N- and C-terminal fragments, including both  
93 duplications and deletions. To isolate deletions in a particular size range, the MISER library was digested with  
94 BsaI, in order to excise the dCas9 gene from the vector backbone, and run on an agarose gel. Various slices  
95 of the MISER library were individually gel extracted (Fig. S2A), ligated into expression vector pSAH063 (Fig.  
96 S2B), and transformed into *E. coli*.

97

98

#### 99 **Fluorescence repression assays and flow cytometry**

100

101 The catalytically dead dCas9 MISER variants were used to repress the transcription of genomically  
102 encoded fluorescent reporter genes in *E. coli* as previously described<sup>1</sup>. A sgRNA targeting Green Fluorescent  
103 Protein (GFP) was transcribed from plasmid pgRNA-bacteria (Addgene ID 44251)<sup>1</sup>, which results in repression  
104 of constitutively expressed GFP, contingent on functional dCas9 expression from pSAH063<sup>2</sup>. This repression  
105 was quantified relative to non-targeted Red Fluorescent Protein (RFP), which is expressed from the same  
106 genomic locus<sup>1</sup>. This assay yields robust repression detection (Fig. S2B), with at least an order of magnitude  
107 lower GFP signal after 8 hours of growth at 37° C with 750 rpm shaking in LB media + 1 nM Isopropyl β-D-1-  
108 thiogalactopyranoside (IPTG) induction of dCas9 from pSAH063. Assays and flow cytometry were conducted  
109 in either an M1000 plate reader (Tecan) or an SH800 Cell Sorter (Sony Biotechnology). For GFP/RFP ratiometric  
110 measurements (Fig. 2A, 3A) there was no significant difference between samples for the RFP fluorescence  
111 measurement.

112

## 113 Deep sequencing

114  
115 100 nucleotide single end reads were used to sequence the dCas9 Slice 4 and Slice 5 libraries. dCas9  
116 open reading frames were amplified from pSAH064 libraries with primers SAH\_356 and SAH\_358. PCR  
117 products were further prepared for deep sequencing by the UC Berkeley Functional Genomics Laboratory.  
118 Sequencing was performed by the UC Berkeley Vincent J. Coates Genomics Sequencing Laboratory on an  
119 Illumina HiSeq4000. Samples were mixed at custom ratios as follows: Slice 5 Naïve Library – 10%; Slice 5  
120 Sorted Library – 10%; Slice 4 Naïve Library – 40%; Slice 4 Sorted Library – 40%. Sequencing analysis was  
121 performed with custom MATLAB scripts available online at <https://github.com/savagelab>. Briefly, reads were  
122 analyzed for the novel presence of the two possible MISER scar sequences, 'GCTAGT' or 'ACTAGC'. The  
123 majority of reads were fully WT dCas9 sequences, as expected due to the fact that scar sequences can occur  
124 anywhere along dCas9. Once detected, reads containing 15 bp upstream and downstream of the scar (that  
125 exactly matched dCas9 sequence) were used to identify the location of a deletion. Sequencing statistics can  
126 be found in Table S3. Enrichment ratios were calculated by taking the ratio of the frequency of each variant  
127 before and after selection<sup>3</sup>. To conservatively display variants only detected in one library, one artificial read  
128 was added to both datasets. The log base ten of these enrichment ratios were plotted (Figure S3 A and B) for  
129 each of the two libraries. For visualization, these two datasets were also normalized according to their Pearson  
130 Correlation (Figure S3 E), combined (the mean was calculated for those variants with two values), and rescaled  
131 for display (Figure 1C and S4 A).

## 134 Protein expression and purification

135  
136 A *Streptococcus pyogenes* Cas9 gene containing nuclease-deactivating mutations D10A/H840A (a.k.a.  
137 dCas9) was cloned into a pET14b expression vector, encoding a N-terminal 6xHis fusion tag and a C-terminal  
138 2xNLS fusion tag. Specific MISER dCas9 variants were cloned by PCR-amplification (Q5 High-fidelity  
139 polymerase, NEB) of the dCas9 gene excluding deleted regions obtained from MISER screen (see Table S4 for  
140 primer sequences). Plasmids were verified by Sanger sequencing (UC Berkeley DNA Sequencing Facility).  
141 dCas9 and MISER constructs were overexpressed in *E. coli* BL21 (DE3) LOBSTR expression system (Kerafast).  
142 Cells were grown in Terrific Broth, modified media with 8 mM MgCl<sub>2</sub> and 0.5 glycerol and induced at ~0.6 OD  
143 with 0.5 mM IPTG. Cells were resuspended in Lysis Buffer (20 mM HEPES pH 7.5, 1 M KCl, 15 mM imidazole,  
144 1 mM TCEP, 10% glycerol, 0.1 mM PMSF, Roche protease inhibitor tablet), lysed by sonication and clarified  
145 by centrifugation, and incubated with Ni-NTA resin to purify soluble fractions. Protein-bound Ni-NTA resin was  
146 washed with Wash Buffer (Lysis Buffer + 0.1% Triton X-114), and eluted (Elution Buffer: 20 mM HEPES pH 7.5,  
147 150 mM KCl, 300 mM imidazole, 1 mM TCEP, 10% glycerol). Eluted fractions were subjected to a Heparin  
148 Sepharose column (GE Healthcare) for ion-exchange chromatography (300 mM KCl to 1 M gradient),  
149 concentrated, and further purified on a gel-filtration column (Superose 6 Increase, GE Healthcare). Protein  
150 Storage Buffer was as follows: 20 mM HEPES pH 7.5, 150 mM KCl, 1 mM TCEP, 10% glycerol. Purified protein  
151 aliquots were flash-frozen in liquid nitrogen and stored at -80°C. Concentrations were measured via Nanodrop  
152 A280 (ThermoFisher Scientific).

**In vitro DNA binding assays**

Purified proteins were complexed with 1.2x molar ratio sgRNA in the presence of 5 mM MgCl<sub>2</sub>. 5'-biotinylated target DNA and corresponding non-target DNA was purchased from IDT as single-stranded oligos and annealed 1:1 according to standard IDT protocols. All bio-layer interferometry (BLI) measurements were performed on an Octet RED384 system (ForteBio). Biosensors coated with streptavidin (SA) were incubated in BLI Buffer (20 mM HEPES pH 7.5, 100 mM KCl, 5 mM MgCl<sub>2</sub>, 10 µg/mL Heparin, 50 µg/mL bovine serum albumin, 0.01% v/v IGEPAL CA-630, 1 mM TCEP, 10% v/v glycerol) for ~10 min prior to assay. 5'-biotinylated target DNA (ligand) and corresponding non-target DNA was purchased from IDT as single-stranded oligos and annealed 1:1 according to standard IDT protocol (See Table S4 for oligo sequences).

Biotinylated dsDNA was diluted in BLI buffer to a concentration of 10 nM. dCas9 or MISER construct RNPs were diluted in BLI Buffer at various concentrations (0.1x to 10x reported K<sub>D</sub>). BLI step sequence was as follows: SA biosensors were incubated in BLI buffer for 60 seconds (baseline); dsDNA ligands were loaded onto SA biosensors for 300 seconds (loading); SA biosensors were incubated in BLI buffer for 60 seconds again to re-equilibrate ligand-bound tip (baseline); dsDNA-functionalized biosensors were incubated with RNP analytes for 1000 seconds (association); and biosensors were incubated in baseline wells from Step 1 for 1000 seconds (dissociation). All steps were performed at 37° C with stirring (1000 RPM). Data analysis was performed with Octet Data Analysis HT software (ForteBio).

**Mammalian CRISPR interference (CRISPRi) assay**

For the mammalian CRISPR interference (CRISPRi) based competitive proliferation assay, human U-251 glioblastoma cells were stably transduced with lentiviral vectors (pSC066) expressing MISER or WT-dCas9 KRAB fusion proteins, followed by selection on puromycin (InvivoGen, #ant-pr-1; 1.0-2.0 µg/ml). The respective cell lines were then transduced with a secondary lentiviral vector (pCF221) expressing mCherry fluorescence protein and either CRISPRi sgRNAs targeting essential genes (sgPCNA, sgRPA1) or non-targeting controls (sgNT). After mixing with the respective parental population (at approximately an 80:20 ratio of transduced to non-transduced cells), the percentage of mCherry positive cells was monitored by flow cytometry (Attune NxT flow cytometer, Thermo Fisher Scientific) over several days to assess the effect of CRISPRi with the given Cas9-variant on cell proliferation. CRISPR interference (CRISPRi) sgRNAs had been previously designed<sup>4</sup>, as were non-targeting sgRNAs<sup>5</sup>. The sgRNAs were designed with a G preceding the 20-nucleotide guide for better expression from U6 promoters and cloned into the pCF221 lentiviral vector for expression<sup>6</sup>.

**Reverse-transcription quantitative PCR (RT-qPCR)**

To measure the efficacy of CRISPRi repression of essential genes by dCas9-MISER constructs in cultured mammalian cells, we performed RT-qPCR of targeted genes in human U-251 glioblastoma cells. Cells were stably transduced with lentiviral vectors encoding dCas9- or MISER-KRAB proteins, and sgRNA targeting PCNA (sgPCNA-i6) as described in the mammalian CRISPRi experiment (including non-targeting guide sgNT-1), except without any mixing with the parental population. Cells were allowed to grow and then harvested 2 and 5 days post-transduction. RNA was extracted using Trizol-chloroform and stored in -80° C<sup>7</sup>. RNA was reverse-transcribed to cDNA with RNA-to-cDNA EcoDry™ Premix with random hexamers (Takara Bio), using

197 manufacturer's protocols. Quantitative PCR (qPCR) amplification of cDNA was performed using primers  
198 specific for *PCNA* (oAS089-92, Table S4) using SYBR Green PCR Master Mix (ThermoFisher Scientific) in a  
199 QuantStudio 3 Real-time PCR System (ThermoFisher Scientific). GAPDH was used as the housekeeping control  
200 (amplified with primers oAS117-118, Table S4). All results are reported relative to the expression of *PCNA* in  
201 cells transfected with non-target gRNA (sgNT-1, Table S4). Only amplification plots below a  $\Delta R_n$  threshold of  
202 0.040 and a  $C_t$  value  $<35$  cycles were used for analysis of expression levels.  $\Delta C_q$  values were calculated by  
203 subtracting  $C_q$  values of GAPDH amplifications from *PCNA*, and  $\Delta\Delta C_q$  values were calculated by subtracting  
204 the non-target samples from the target samples. Fold-change in expression is reported as  $2^{-\Delta\Delta C_q}$ .

### 207 **Cryo-electron microscopy sample preparation and image acquisition**

209 The ternary complex was prepared at 37 °C using a  $\Delta 4CE$ , sgRNA, and dsDNA target at a ratio of 1:1.5:2  
210 in complexing buffer (30 mM Tris-HCl, pH 8.0, 150 KCl, 5 mM  $MgCl_2$ , 5 mM DTT, 2.5 % glycerol). Protein and  
211 sgRNA were incubated for 30 minutes prior to addition of dsDNA for an additional 1 hour of incubation. The  
212 sample was then desalted using a spin-column (Zeba) into Complexing Buffer containing 0.1% glycerol to be  
213 used for grid preparation. To prepare the sample for imaging, 3.2  $\mu L$  of the ternary complex (around 30 nM) was  
214 applied to R1.2/1.3 Cu 200 grids (Quantifoil) coated with a thin layer of homemade continuous carbon that had  
215 been glow-discharged for 15 s immediately before use. The sample was incubated on the grid at 100% humidity  
216 and 16 °C for 10 s prior to blotting for 5 s with filter paper and plunging into liquid ethane cooled to liquid  
217 nitrogen temperatures using a Vitrobot Mark IV (TFS). The sample was imaged using a Talos Arctica  
218 transmission electron microscope (TFS) operated at 200 kV and equipped with a K3 direct electron detector  
219 (Gatan) at the Bay Area Cryo-EM facility at the University of California, Berkeley. Movies were recorded in super-  
220 resolution counting mode at an effective pixel size of 0.45 Å, with a cumulative exposure of 60  $e^- \cdot \text{Å}^{-2}$  distributed  
221 uniformly over 60 frames. Automated data acquisition was performed using image-shift and active beam tilt  
222 compensation as implemented in SerialEM-v3.7 to acquire movies from a 3x3 array of holes per stage  
223 movement<sup>8</sup>. In total, 3400 movies were acquired with a realized defocus range of -1.5 to -3.8  $\mu m$ .

### 226 **Cryo-EM image processing**

228 All steps were performed using RELION-v3.1b unless otherwise indicated<sup>9</sup>. Movies were motion-  
229 corrected, exposure-filtered, and Fourier cropped to a pixel size of 0.9 Å using and the initial CTF parameters  
230 estimated by CTFFIND-v4.1.13<sup>10</sup>. Micrographs were culled by thresholding for CTF-fit resolutions better than  
231 8 Å and manual curation to yield a set of 2554 micrographs used in further processing. An initial set of 97,827  
232 particles were picked using the general model of Boxnet2<sup>11</sup>. These particles were extract in a 256 pixel box  
233 Fourier cropped to 64 pixels (3.6 Å·px<sup>-1</sup>). Iterative rounds of reference-free 2D classification resulted in 85,327  
234 particles, which were used to generate an ab initio 3D-reference by stochastic gradient descent. Particles were  
235 re-extracted and upsampled in a 128 pixel box (1.8 Å·px<sup>-1</sup>) for further processing. Unsupervised 3D  
236 classification did not resolve distinguishable classes. Thus, all particles were subjected to 'gold-standard' 3D  
237 auto-refinement using a reference low-pass filtered to 25 Å and a soft shape-mask. This yielded a  
238 reconstruction at a nominal resolution of 6.4 Å based on the FSC0.143 criterion and using phase-randomization  
239 to correct for masking artifacts<sup>12</sup>. This set of particles was then used to train a picking model with Topaz-v0.2.3  
240<sup>13</sup>. This approach resulted in a set of 288,416 particle coordinates. The new set of particles was extracted in a

241 128 pixel box ( $1.8 \text{ \AA} \cdot \text{px}^{-1}$ ) and subjected to reference-free 2D classification, which resulted in a set 167,245  
242 particles. Additional attempts at 3D classification did not resolve distinguishable classes. This final set of  
243 particles was used for 3D auto-refinement as described above and resulted in a  $6.2 \text{ \AA}$  reconstruction. Further  
244 processing using reference-based fitting of particle motion and CTF parameters did not yield improvements.  
245 Resolution anisotropy of the final reconstruction was assessed using the 3DFSC web server <sup>14</sup>.  
246

247

248

### 248 **Modelling of the cryo-EM map**

249


250 The previously published coordinate model for the  $5.2 \text{ \AA}$  cryo-EM structure of SpCas9 ternary complex  
251 (PDB ID 5Y36) was used as an initial model <sup>15</sup>. To this end, the protein domains were deleted from 5Y36 to match  
252 those of  $\Delta 4\text{CE}$ . The unresolved 5'-end of the non-target strand was also removed. The edited coordinate model  
253 was then docked as a rigid-body into the RELION post-processed map using ChimeraX-v1.0, which resulted in  
254 a cross-correlation value of 0.76 against a  $6.2 \text{ \AA}$  map simulated from the coordinate model <sup>16</sup>. For display  
255 purposes, a denoised version of the  $\Delta 4\text{CE}$  map was generated with LAFTER as part of the CCPEM-v1.4.1 suite  
256 <sup>17</sup>.

257 **Supporting Figures**

258

259 **Figure S1.**

260



261


262

263 **Figure S1: Full cloning scheme for Multiplex Iterative Size Exclusion Recombination (MISER).** The method  
 264 can be considered in three parts. **A)** Plasmid recombineering generates two comprehensive libraries of  
 265 restriction site insertions across the target gene. These restriction sites are both novel to the target plasmid and  
 266 produce compatible sticky ends. Recombineering was performed similarly as in (Higgins 2017), where the target  
 267 gene lacks a promoter and start codon to prevent growth biases during library construction and is flanked by  
 268 Bsal sites for later Golden Gate cloning (here, plasmid pSAH060). Additionally, rather than mutagenic oligos,  
 269 double stranded PCR product was used for recombineering, and another cloning step was introduced to  
 270 remove unmodified plasmids. These modifications are described in Experimental Design. **B)** Modified golden  
 271 gate cloning generates a library of ligated N- and C- terminal fragments of the target gene, comprehensively  
 272 producing protein deletion variants as well as duplication variants. An equimolar mixture of the two plasmid  
 273 libraries is mixed and fully digested to produce free N- and C- terminal fragments of the target gene. This  
 274 fragment mixture is then re- ligated in the presence of NheI and SpeI. Successful ligation of an N- and C-  
 275 terminal fragment from differing libraries produces one of two possible 6 base-pair scar sequences. These novel  
 276 scar sequences are not recognized by either NheI or SpeI, thus trapping the desired chimeric product as a final  
 277 ligated vector. Because N- and C-terminal fragments are ligated randomly, these chimeric products produce  
 278 both protein deletions and protein duplications. Ideally the library is both large enough and minimally biased in  
 279 order to produce a large fraction of possible variants. The product of this step can be considered a MISER  
 280 library of plasmid pSAH060. **C)** A final cloning step moves the MISER library into a desired context – i.e. an  
 281 expression plasmid, here pSAH063. Step C also allows for size-based exclusion of undesired protein variants  
 282 by extraction from an agarose gel (Figure 1 and Figure S2).



283 **Figure S2.**


284



285

286

287 **Figure S2: Size exclusion and flow cytometry identify the range of dCas9 deletion sizes exhibiting *in vivo***  
 288 **transcriptional repression. A)** To empirically determine the size range of functional deletions, an agarose gel  
 289 of the dCas9 MISER deletion library was sliced into six sub-libraries, independently cloned into expression  
 290 vectors (B), and assayed for CRISPRi GFP repression via flow cytometry (C). Sublibrary Slice 4 was the most  
 291 stringent library with detectable repression, with functional variants becoming more frequent in slices composed  
 292 of smaller deletions as expected. **B)** The six gel slices in (A) were individually gel extracted and ligated into  
 293 expression vector pSAH063, generating pSAH064 plasmids with dCas9 deletions. The resulting expression  
 294 sub-libraries exhibit high precision in size ranges when assayed by agarose gel electrophoresis. **C)** Flow  
 295 cytometry identifies Slice 4, 5, and 6 as expression sub-libraries containing functional dCas9 deletion variants.  
 296 GFP repression CRISPRi was performed as described in Experimental Design. The region of phenotype defined  
 297 as 'functional' is illustrated. The percent of functional hits is annotated.

298 **Figure S3**


299

300

**Figure S3: Deep sequencing of the sublibraries of Slice 4 and Slice 5 reveal deletion regions throughout dCas9.** **A)** Raw enrichment map of Slice 4 sub-library. Each pixel represents a single deletion variant, whose start and end points are the axis intercepts when moving down and to the left or right, respectively, as described in the main text. Domain boundaries are labeled by amino acid number. The pixel color also denotes the degree of enrichment or loss following flow cytometry screening for transcriptional repression in vivo. Detailed calculations are described in the supplementary methods. Deletions corresponding to sizes within the gel slice are indicated by dashed lines. **B)** Raw enrichment map of Slice 5 sub-library, as in (A). Note the differing range of enrichment ratios. **C)** Histogram of deletion sizes in the naïve Slice 4 library. The hypothetical edges of the gel slice are indicated by dashed lines. **D)** Histogram of deletion sizes in the naïve Slice 5 library. The edges of the gel slice are indicated by dashed lines. **E)** Slices 4 and 5 independently replicate the same large functional deletion regions. The raw enrichment maps of Slice 4 and Slice 5 contain many of the same variants, and the Pearson correlation for these variants is highly significant ( $p < 0.001$ ). Furthermore, this correlation is progressively lost if the two enrichment maps are shifted relative to one another. The line plots the mean of four additional Pearson correlations where the data array has been offset – either up, down, left, or right – by the indicated number of amino acids. This analysis verifies that the two enrichment maps independently identify large-scale regions of dCas9 which can be deleted and validates the apparent visual correspondence between maps A and B. Error bars, standard deviation.

318 **Figure S4.**

319




320

321

322 **Figure S4: Key elements of dCas9 secondary structure are revealed by the functional impact of small**  
 323 **deletions and insertions. A)** The enrichment map of Figure 1C is presented in its entirety, including small  
 324 duplications of dCas9 sequence. The horizontal grey line corresponds to the boundary between deletions (top)  
 325 and tandem duplicate insertions (bottom). Note that in all cases a two amino acid MISER scar is also present  
 326 (either Ala-Ser or Thr-Ser) which is not included in display or numbering. **B)** The combined enrichment map in  
 327 (A) was interpolated to highlight the boundaries between functional and non- functional deletions, which are  
 328 not clearly visible in the raw data. Pixels were replaced by the mean enrichment value of neighboring  
 329 deletions/duplications, plus itself, in a square window 10 amino acids wide. Windows with fewer than five values  
 330 were left white. Insets: The N- and C- terminal regions were particularly well resolved by this method, and  
 331 elements of interest are annotated. The 'bridge helix' and 'phosphate lock loop' are two examples of secondary  
 332 structure which strongly disallow small insertions.

333 **Figure S5.**

334



335


336

337 **Figure S5: MISER sublibraries composed of specific deletions can be generated by restriction digestion.**

338 **A)** Digesting a MISER library with a restriction enzyme that has exactly one site within the plasmid will linearize  
 339 the majority of plasmids, while plasmids with the site deleted will remain circular. This reaction can then be  
 340 transformed in order to recover a sublibrary containing deletions from a specific region. **B)** For example, the  
 341 restriction enzyme Swal was used to isolate deletions in the REC2 region. The enzyme recognition site is shown  
 342 mapped to the sequence of pSAH064, the dCas9 expression plasmid, illustrating the overlap with various  
 343 sequenced deletions. **C)** The restriction enzyme KpnI was used to isolate deletions in the REC3 region, as in B.  
 344 **D)** The restriction enzyme PciI was used to isolate deletions in the HNH region, as in B. **E)** Sublibraries  
 345 containing regional individual deletion variants were re-transformed, and colonies were picked and assayed  
 346 for CRISPRi activity. A subset of the most active clones was Sanger sequenced to identify the precise deletion.  
 347 RuvC deletions could not be isolated by the sublibrary approach, and instead were cloned manually by PCR.  
 348 Data are plotted as mean $\pm$ SD from biological triplicates.

349 **Figure S6.**

350




351

352

353 **Figure S6: Golden Gate Cloning builds libraries of CRISPR Effector (CE) variants with multiple deletions.**

354 **A)** One highly functional RuvC deletion variant from Region D was PCR amplified, along with Sublibraries A, B,  
 355 and C. PCR primers added Golden Gate compatible sticky ends, enabling Golden Gate cloning of individual  
 356 fragments to form a library of CE deletion variants, Library 1. **B)** Flow cytometry was performed to isolate the  
 357 most functional CE variants from the “stacked” library described in (A). All highly functional CE variants from  
 358 Library 1 were found to lack REC2 deletions (sequences of CE variants selected for display on this plot can be  
 359 found in Table S3). To verify this result, a second version of Sublibrary A was created, using a different strategy  
 360 to isolate REC2 deletions as follows: the full MISER library was digested with the restriction enzyme BspI, which  
 361 cuts at amino acids 227-228 (instead of SwaI), and the resulting DNA was used directly as template for the PCR  
 362 reaction (BspI cuts pSAH064 three times and thus cannot be directly re-transformed to isolate the sublibrary).  
 363 Library 2 thus contains all four deletion variants as in Library 1, except the sublibrary of REC2 deletions was  
 364 entirely remade. However, once again functional CE variants isolated by FACS lacked REC2 deletions. The  
 365 most functional variant in Library 2, CE 13, was named  $\Delta 3\text{CE}$ . Finally, to directly assay the effects of a REC2  
 366 deletion, the REC2 region of  $\Delta 3\text{CE}$  was replaced with a library of deletions from Sublibrary A. These quadruple  
 367 deletion CE variants all exhibited vastly reduced CRISPRi activity compared to  $\Delta 3\text{CE}$  alone. The most functional  
 368 variant assayed was named  $\Delta 4\text{CE}$ . Data are plotted as mean $\pm$ SD from biological triplicates.

369 **Figure S7.**

370

371 **Figure S7: 3D comparison of complete dCas9-sgRNA-dsDNA complex and modeled MISER constructs.**

372 Model of SpCas9 complexed with sgRNA and dsDNA (PDB 5Y36), and MISER domain deletions overlaid. Δ3CE


373 contains the REC3, HNH, and RuvC deletions, and Δ4CE contains the additional REC2 deletion, as described

374 in Fig. 2 and S5. The Δ4CE model is shown with the domains corresponding to MISER deletions hidden.

375 Molecular weights are calculated by the ExpPASy ProtParam tool (<https://web.expasy.org/protparam/>).

376 **Figure S8.**

377




378

379

380 **Figure S8: Spacer sequence-dependent variability in repression activity of  $\Delta$ REC3.** **A)** Plot showing fold-  
 381 change in repression by  $\Delta$ REC3 for different targets versus fraction of G-C content in seed region. Correlation  
 382 between G-C content and repression is low and does not fully explain the variability in repression seen by the  
 383  $\Delta$ REC3 construct across different target sequences. **B)** WebLogo showing spacer sequence variability for  
 384 guides that exhibit at least a three-fold loss in repression by  $\Delta$ REC3 compared to dCas9. **C)** Schematic showing  
 385 the process of gRNA invasion into the dsDNA target leading to R-loop formation by Cas9. In Step 1, unwinding  
 386 of the dsDNA double-helix is initiated at 1-2 bases adjacent to the PAM in the seed region, creating a  
 387 destabilized region where the gRNA can invade, in Step 2. Hybridization of the gRNA to the target strand occurs  
 388 in the seed region and proceeds in the PAM-distal direction (3'  $\rightarrow$  5'), until the entire spacer sequence (~20bp)  
 389 is annealed to the target strand, generating an RNA-DNA duplex called an R-loop (Step 3). RNA-DNA hybrid is  
 390 shown as a 2-D representation for clarity instead of a helix.

391 **Figure S9.**


392





400 **Figure S10.**

401




402

403

404 **Figure S10: Bio-layer interferometry (BLI) controls. A)** BLI experiments were performed by incubating  
 405 immobilized dCas9 with dsDNA containing a target spacer but no PAM (orange trace). Transient PAM  
 406 interactions have a significant contribution to the  $k_{on}$  of association. The signal is lost immediately in the  
 407 dissociation step, which suggests that the interaction is nonspecific. Conversely, incubation with a dsDNA  
 408 containing no spacer and no PAM shows no signal (purple). **B)** BLI traces of  $\Delta 3CE$  and  $\Delta 4CE$  binding to dsDNA  
 409 show that the relative binding is minimal at 300 nM, even with a 3-bp bubble in the seed region of the target  
 410 (orange and purple). Subsequently a concentration of 1000 nM was used for these constructs. Light grey and  
 411 dark grey traces represent  $\Delta 3CE$  and  $\Delta 4CE$  RNPs, respectively, against dsDNA without a spacer or PAM. All  
 412 data shown are normalized to the maximum signal of dCas9 vs. fully complementary dsDNA target (black).

413 **Figure S11.**

414




415

416

417 **Figure S11: Schematic of CRISPR interference (CRISPRi) based survival assay. A)** U-251 glioblastoma  
 418 cells are stably transduced with lentiviral vectors (pSC066) expressing MISER-dCas9 or WT-dCas9 KRAB  
 419 fusion proteins, followed by selection on puromycin. The various cell lines are then transduced with a secondary  
 420 lentiviral vector (pCF221) expressing mCherry fluorescence protein and either sgRNAs targeting essential genes  
 421 (sgPCNA) or non-targeting sgRNAs (sgNT) as controls. Cells are grown and harvested 2 and 5 days post-  
 422 infection for RNA extraction, followed by RT-qPCR to quantitate transcription of targeted essential genes under  
 423 MISER-KRAB repression. **B)** PCNA  $\Delta\Delta C_q$  values from RT-qPCR at 2 (solid) and 5 (hatched) days post infection,  
 424 calculated by subtracting target samples from sgNT samples. Values are plotted from biological duplicates as  
 425 mean  $\pm$  S.D.

426 **Figure S12.**

427



428

429

430 **Figure S12: Single-particle cryo-EM of the  $\Delta 4$ Cas9 ternary complex.** **A)** Exemplar micrograph at  
 431 approximately 3 microns defocus with scale indicated and representative reference-free 2D class averages  
 432 from the Topaz-picked particle set. Diameter of 2D mask is 150 Å in all averages. **B)** Single-particle  
 433 reconstruction work-flow as described in methods and orientation distribution of the final reconstruction inset.  
 434 **(C)** Directional FSC for final reconstruction. **D)** and **E)** Local resolution estimates calculated in RELION shown  
 435 by coloration on the map and as a histogram, respectively. **F)** Density map of  $\Delta 4$ CE with putative domains  
 436 colored according to their relative position within a 20 nm radius when overlaid on WT SpCas9 (PDB 5Y36).

437 **Table S1.**

438

	<b>SpeI Insertion</b>	<b>NheI Insertion</b>
<b>Recombineering Oligo: Insertion Site 1</b>	AACACGTCCTAGAACTcgtctcatagcaa Accgcctctccccgcgcgttggcggtctcaatct <u>ATGactagtgataagaaatactcaataggcttag</u> ctatcggcacaatagcgtcgggagacgGCAAGC GGTAACTCAGATCAGTGTGAGCGTAACCAAGT	AACACGTCCTAGAACTcgtctcatagcaa Accgcctctccccgcgcgttggcggtctcaatct <u>ATGgctagcgataagaaatactcaataggcttag</u> ctatcggcacaatagcgtcgggagacgGCAAGC GGTAACTCAGATCAGTGTGAGCGTAACCAAGT

439

440 **Table S1: Example Oligo Library Synthesis (OLS) oligonucleotides used in this study.** The full list of ordered  
441 oligonucleotides is available as 'Auxiliary Supplementary Materials - Recombineering Oligonucleotides'. All  
442 oligonucleotides were ordered from Agilent Technologies, Inc. Oligos were designed to incorporate 45 and 47  
443 bp of homology upstream or downstream of the insertion site, respectively (lowercase). Six bp were inserted  
444 between dCas9 codons, beginning after the target codon. The above example targets the start codon, 'ATG'  
445 (bold uppercase). These six bp consisted of recognition sequences for either the restriction enzyme SpeI or  
446 NheI (underlined). Flanking primer sequences allowed the amplification of the entire OLS library (italics) using  
447 oligonucleotides SAH\_284 and SAH\_285 (Table S6). Specific libraries of SpeI recombineering oligonucleotides  
448 or NheI recombineering oligonucleotides were amplified using forward primer SAH\_284 and either SAH\_286 or  
449 SAH\_287 reverse primers, respectively. After amplification, these dsDNA products can be 'matured' by  
450 cleavage with the restriction enzyme Bsmbl (bold lowercase), which cleaves internally of its recognition site,  
451 thus removing all non-homologous priming sequence from the recombineering template.

452 **Table S2.**

453

Deletion	CE1	CE2	CE3	CE4	CE5	CE6	CE17	CE21	CE22	$\Delta$ 3CE	$\Delta$ 4CE
<b>REC2</b>	-	-	-	-	-	-	-	-	-	-	[180-297]
<b>REC3</b>	[511-716]	[498-699]	[500-688]	[497-700]	[501-664]	[512-721]	[509-650]	[508-649]	[508-646]	[503-708]	[503-708]
<b>HNH</b>	[813-909]	[813-908]	[811-898]	[786-882]	[804-893]	[809-916]	[776-923]	[768-900]	[786-923]	[792-897]	[792-897]
<b>RuvC</b>	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]	[1010-1081]

454

455 **Table S2:** Deletions present in selected MISER variants. Indicated numbers represent the first and last  
456 amino acid deleted from the protein.

457 **Table S3.**

458

	<b>Total Reads</b>	<b>Deletions Sequenced</b>	<b>Unique Deletions</b>	<b>Enriched Unique Deletions</b>	<b>De-enriched Unique Deletions</b>
<b>Slice 4 Naïve</b>	132,274,232	1,923,543	192,447		
<b>Slice 4 Sorted</b>	140,589,968	1,960,138	25,948	19,618	6,330
<b>Slice 5 Naïve</b>	37,873,068	590,859	111,438		
<b>Slice 5 Sorted</b>	35,016,326	290,947	51,462	31,794	19,668
<b><u>Total</u></b>	<u>345,753,594</u>	<u>4,765,487</u>	<u>381,295</u>	<u>51,412</u>	<u>25,998</u>

459

460 **Table S3: Statistics for deep sequencing of MISER libraries Slice 4 and Slice 5.**

461 **Table S4.**

462

Gene	Distance from RBS (bp)	PAM-proximal 10bp sequence (5'-3')	PAM-proximal G-C fraction	Fold loss	Std. dev.
<b>GFP</b>	<b>38</b>	<b>AACAAGAATT-NGG</b>	<b>0.2</b>	<b>2.54</b>	<b>0.23</b>
RFP	124	TTAGCGGTCT-NGG	0.5	37.84	3.78
<b>GFP</b>	<b>130</b>	<b>ATAAATTTAA-NGG</b>	<b>0.0</b>	<b>2.11</b>	<b>0.01</b>
<b>GFP</b>	<b>174</b>	<b>TGACAAGTGT-NGG</b>	<b>0.4</b>	<b>1.23</b>	<b>0.02</b>
<b>GFP</b>	<b>196</b>	<b>TGAACACCAT-NGG</b>	<b>0.4</b>	<b>2.14</b>	<b>0.10</b>
<b>GFP</b>	<b>225</b>	<b>TCATGTGATC-NGG</b>	<b>0.4</b>	<b>0.96</b>	<b>0.05</b>
GFP	262	CCTTCGGGCA-NGG	0.7	22.77	0.73
<b>GFP</b>	<b>316</b>	<b>CGCGTCTTGT-NGG</b>	<b>0.6</b>	<b>1.18</b>	<b>0.06</b>
<b>GFP</b>	<b>355</b>	<b>CGATTAACAA-NGG</b>	<b>0.3</b>	<b>1.50</b>	<b>0.06</b>
RFP	111	TACCTTCGTA-NGG	0.4	8.54	0.50
RFP	130	TTCAGTTTAG-NGG	0.3	14.56	0.77
<b>RFP</b>	<b>165</b>	<b>CCCAAGCGAA-NGG</b>	<b>0.6</b>	<b>3.13</b>	<b>0.06</b>
RFP	182	CTGCGGGGAC-NGG	0.8	21.35	0.71
RFP	197	GGAACCGTAC-NGG	0.6	6.98	0.23
RFP	208	ACGTAAGCTT-NGG	0.4	13.79	2.92
RFP	239	CAGGTAGTCC-NGG	0.6	20.74	4.25
RFP	248	GGACAGTTTC-NGG	0.5	12.10	0.60

463

464 **Table S4: gRNA target loci and G-C content dependence of  $\Delta$ REC3 repression.** Spacer sequences  
465 highlighted in blue were used to generate the WebLogo in Figure S9A.

466 **Table S5.**

467

<b>EMDB-22518</b>	
<b>Data Collection</b>	
Microscope	Talos Arctica
Magnification	45,000
Voltage (kV)	200
Detector	K3
Electron exposure (e-/Å <sup>2</sup> )	60
Defocus range (µm)	1.5 to 3.8
Pixel size (Å)	0.45 <sup>a</sup>
<b>Reconstruction</b>	
Symmetry imposed	C1
Box size (pixels/Å)	128/230
Initial particle images (no.)	288,416 <sup>b</sup>
Final particle images (no.)	167,245
Map resolution (Å)	6.2
FSC threshold	0.143
Sharpening factor (Å <sup>2</sup> )	-395
Map resolution range (Å)	5.5-9.5
Sphericity	0.831
<b>Modeling</b>	
Method	Rigid-body
Initial Model	5Y36
CC	0.75

468 <sup>a</sup>Super-resolution469 <sup>b</sup>from picking with Topaz

470

471 **Table S5: Cryo-EM data collection & reconstruction statistics.**



472 **Table S6.**

Oligo ID	Purpose	Sequence (5'-3')
SAH_284	Recombineering amplification: universal forward	AACACGTCCTAGAACT
SAH_285	Recombineering amplification: universal reverse	ACTTGGTTACGCTCAACACT
SAH_286	Recombineering amplification: Spel-specific reverse	GATCTGAGTGTACCGCTTGC
SAH_287	Recombineering amplification: NheI-specific reverse	GATCGCCTAGACAACCTCTG
sgRNA-B9	sgRNA for Cas9 RNP, used in BLI and cryo-EM	AGUCGGUGUCGACCCGGACCCAAAUCUCGAUCUUUAUCGUUCAUUUU AUUCCGAUCAGGCAAUAGUUGAACUUUUUACCCGUGGCUCAGCCACGAA AA
oAS081	5'-biotinylated ssDNA target for BLI, sgRNA-B9	GCTCAATTTTGACAGCCCACCAGGCCAGCTGTGGCTGATGGCATCCTT CCTCTC
oAS003a	non-target ssDNA for BLI (complementary to oAS081)	GAGTGGAAGGATGCCATCAGCCACAGCTGGGCTGGTGGGCTGTCAAAA TTGAGC
oAS114	5'-biotinylated ssDNA non-target for BLI (no spacer, no PAM)	GTGTGCACACATGCAATAACATTGTGCACATGATACATTGCAATGACAA TTAACC
oAS036	non-target ssDNA for BLI (complementary to oAS081, 3-bp PAM-proximal bubble)	GAGTGGAAGGATGCCATCAGCCACAGCTGGGCCGATTGGGCTGTCAAAA TTGAGC
oAS116	unlabeled ssDNA target for BLI, sgRNA-B9. Used for cryo-EM RNP complex	GCTCAATTTTGACAGCCCACCAGGCCAGCTGTGGCTGATGGCATCCTT CCTCTC
sgNT-1	Non-targeting gRNA for mammalian CRISPRi	GGCCAAACGTGCCCTGACGG
sgNT-2	Non-targeting gRNA for mammalian CRISPRi	GCGATGGGGGGTGGGTAGC
sgPCNA-i1	PCNA targeting gRNA for mammalian CRISPRi	GGGGCGAACGTGCGCAGCAGC
sgPCNA-i2	PCNA targeting gRNA for mammalian CRISPRi	GGCGTGGTACGTCGCAACG
sgPCNA-i3	PCNA targeting gRNA for mammalian CRISPRi	GCGCTCCCAGCAAGCACC
sgPCNA-i4	PCNA targeting gRNA for mammalian CRISPRi	GAAGCGCTCCCAGCAAGCAGC
sgPCNA-i5	PCNA targeting gRNA for mammalian CRISPRi	GCCCGGCCGCTGCACCTC
sgPCNA-i6	PCNA targeting gRNA for mammalian CRISPRi	GCGGACGCGCGGCATTAAA
sgPCNA-i10	PCNA targeting gRNA for mammalian CRISPRi	GGCCATCCGCGCTTCTCAT
sgRPA1-i1	RPA targeting gRNA for mammalian CRISPRi	GGGAAGCTGGAGCTGTTGCG
sgRPA1-i2	RPA targeting gRNA for mammalian CRISPRi	GGCGACGGGGATGAACGCG
sgRPA1-i3	RPA targeting gRNA for mammalian CRISPRi	GTGCGCAGCGCGGGACCC
sgRPA1-i4	RPA targeting gRNA for mammalian CRISPRi	GTGAGCCGCGCAGCTCGG
sgRPA1-i5	RPA targeting gRNA for mammalian CRISPRi	GGCGGTGCGCGCAACTTCTC
sgRPA1-i8	RPA targeting gRNA for mammalian CRISPRi	GCGAGCCTCGGGAGTAGAG
sgRPA1-i9	RPA targeting gRNA for mammalian CRISPRi	GCCGCGCGCTGCGCAGTTAT
oAS085	Forward primer for RPA1 cDNA reverse transcription, set 1	GCAGTTGGAGTGAAGATTGG
oAS086	Reverse primer for RPA1 cDNA RT, set 1	CACTTGGACTGGTAAGGAGT
oAS087	Forward primer for RPA1 cDNA RT, set 2	CCGAGCTACAGCTTTCAATG
oAS088	Reverse primer for RPA1 cDNA RT, set 2	GCAGATCCCAGTATGTCTA
oAS089	Forward primer for PCNA cDNA RT, set 1	ACTCAAGGACCTCATCAACG
oAS091	Reverse primer for PCNA cDNA RT, set 1	TGAACCTCACAGTATGTCC
oAS090	Forward primer for PCNA cDNA RT, set 2	CGTTATCTTCGGCCCTTAGT
oAS092	Reverse primer for PCNA cDNA RT, set 2	CGTGCAAATTCACCAGAAGG
oAS117	Forward primer for GAPDH RT	TCAAGGCTGAGAACGGGAAG
oAS118	Reverse primer for GAPDH cDNA RT	TGGACTCCACGACTACTCA
oAS034	Forward primer for cloning dCas9 and MISER constructs into expression vector	GGTATCAACTTTTCGTTTCTT
oAS035	Reverse primer for cloning dCas9 and MISER constructs into expression vector	CAAAGCCCGAAAGGAAG

473 **Table S6: Oligonucleotides used in this study.**

474 **References**

475

- 476 1. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173–  
477 1183 (2013).
- 478 2. Oakes, B. L., Nadler, D. C. & Savage, D. F. Protein engineering of Cas9 for enhanced function. *Meth. Enzymol.* **546**, 491–511  
479 (2014).
- 480 3. Fowler, D. M. & Fields, S. Deep mutational scanning: a new style of protein science. *Nat. Methods* **11**, 801–807 (2014).
- 481 4. Horlbeck, M. A. *et al.* Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation.  
482 *Elife* **5**, (2016).
- 483 5. Adamson, B. *et al.* A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein  
484 Response. *Cell* **167**, 1867–1882.e21 (2016).
- 485 6. Oakes, B. L. *et al.* CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification. *Cell* **176**, 254–267.e16  
486 (2019).
- 487 7. Staahl, B. T. *et al.* Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes.  
488 *Nat. Biotechnol.* **35**, 431–434 (2017).
- 489 8. Schorb, M., Haberbosch, I., Hagen, W. J. H., Schwab, Y. & Mastronarde, D. N. Software tools for automated transmission electron  
490 microscopy. *Nat. Methods* **16**, 471–477 (2019).
- 491 9. Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data  
492 sets in RELION-3.1. *IUCrJ* **7**, 253–267 (2020).
- 493 10. Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J. Struct. Biol.* **192**, 216–  
494 221 (2015).
- 495 11. Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. *Nat. Methods* **16**, 1146–1152 (2019).
- 496 12. Chen, S. *et al.* High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by  
497 single particle electron cryomicroscopy. *Ultramicroscopy* **135**, 24–35 (2013).
- 498 13. Bepler, T., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM. *BioRxiv* (2019).  
499 doi:10.1101/838920
- 500 14. Tan, Y. Z. *et al.* Addressing preferred specimen orientation in single-particle cryo-EM through tilting. *Nat. Methods* **14**, 793–796  
501 (2017).
- 502 15. Huai, C. *et al.* Structural insights into DNA cleavage activation of CRISPR-Cas9 system. *Nat. Commun.* **8**, 1375 (2017).
- 503 16. Goddard, T. D. *et al.* UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* **27**, 14–25 (2018).
- 504 17. Ramlal, K., Palmer, C. M. & Aylett, C. H. S. A local agreement filtering algorithm for transmission EM reconstructions. *J. Struct.*  
505 *Biol.* **205**, 30–40 (2019).

506